353 related articles for article (PubMed ID: 26069307)
1. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
[TBL] [Abstract][Full Text] [Related]
2. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.
Rohren EM; Etchebehere EC; Araujo JC; Hobbs BP; Swanston NM; Everding M; Moody T; Macapinlac HA
J Nucl Med; 2015 Oct; 56(10):1507-12. PubMed ID: 26135112
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy.
Etchebehere EC; Araujo JC; Milton DR; Erwin WD; Wendt RE; Swanston NM; Fox P; Macapinlac HA; Rohren EM
Clin Nucl Med; 2016 Apr; 41(4):268-73. PubMed ID: 26828141
[TBL] [Abstract][Full Text] [Related]
4. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
[TBL] [Abstract][Full Text] [Related]
5. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
[TBL] [Abstract][Full Text] [Related]
6. Uptake of Radium-223 Dichloride and Early [
Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
[TBL] [Abstract][Full Text] [Related]
8. Baseline
García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
[TBL] [Abstract][Full Text] [Related]
9. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
[TBL] [Abstract][Full Text] [Related]
10. 18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer.
Brito AE; Santos A; Sasse AD; Cabello C; Oliveira P; Mosci C; Souza T; Amorim B; Lima M; Ramos CD; Etchebehere E
Oncotarget; 2017 May; 8(22):36001-36011. PubMed ID: 28415595
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Assessment of Early [
Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
[TBL] [Abstract][Full Text] [Related]
12. Is interim
Etchebehere E; Brito AE; Kairemo K; Rohren E; Araujo J; Macapinlac H
Radiol Bras; 2019; 52(1):33-40. PubMed ID: 30804613
[TBL] [Abstract][Full Text] [Related]
13. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
Sun Y; Lu P; Yu L
Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
[TBL] [Abstract][Full Text] [Related]
14. Prospective Study of Serial
Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM
J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
[TBL] [Abstract][Full Text] [Related]
15. Interim and end-treatment
García Vicente AM; Amo-Salas M; Cassinello Espinosa J; Gómez Díaz R; Soriano Castrejón Á
Sci Rep; 2021 Apr; 11(1):7389. PubMed ID: 33795764
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Value of Quantitative Bone SPECT/CT Before
Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
[TBL] [Abstract][Full Text] [Related]
19. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
[TBL] [Abstract][Full Text] [Related]
20. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.
Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Pinski JK; Quinn DI
J Nucl Med; 2013 Aug; 54(8):1195-201. PubMed ID: 23785174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]